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Summary A new, simple and sensitive low pH ELISA method has been developed to measure serum levels
of tumour associated antigens detectable by monoclonal antibodies HMFG1 and HMFG2. We examined sera
from healthy controls, patients with neoplastic and non-neoplastic conditions of breast, liver and gastro-
intestinal tract. The majority of patients with metastatic breast cancer had elevated serum antigens (69%
HMFG1, 72% HMFG2) compared to healthy controls (6.3% HMFG1, 3.0% HMFG2) or patients with
benign breast disease (17% HNFG1, 4% HMFG2). There was no discrimination using these assays between
patients with neoplastic and non-neoplastic conditions of liver and gastrointestinal tract. This new method
promises to be ofvalue in the assessment and management of patients with breast cancer.
In the minority of neoplasms, serum tumour
markers can sensitively predict the presence of
disease and can help to monitor the effects of
treatment. The fl-subunit of human chorionic
gonadotrophic (HCG) and a-fetoprotein (AFP) in
germ cell tumours (Lange et al., 1976), placental
alkaline phosphatase (PLAP) in seminoma of testes
(Epenetos et al., 1985), and CA125 in epithelial
ovarian cancer (Bast, et al., 1983)), are examples of
clinically useful tumour markers. Although elevated
serum levels of several markers have been reported
in patients with breast cancer the sensitivity and
specificity of detection have been inadequate for
early diagnosis and monitoring therapy (Burchell et
al., 1984; Ceriani et al., 1982; Coombes et al., 1985;
Cove et al., 1979; Goodall et al., 1985; Lamoureaux
et al., 1982; Wang et al., 1984; Waalkes et al.,
1978).
In this report we describe a new, simple and
sensitive method that measures tumour associated
antigens detected by monoclonal antibodies
HMFG1 and HMFG2. Serum levels of these anti-
gens were found to be elevated in the majority of
patients with breast cancer but only in a few cases
of patients with benign breast disease of healthy
blood donors.
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Materials and methods
Monoclonal antibodies
HMFG1, HMFG2: These mouse IgGI antibodies
were raised against delipidated preparation of the
human milk fat globule. The mouse used for the
development of HMFG2 also received cultured
milk epithelial cells (Taylor-Papadimitriou et al.,
1981; Arklie et al., 1981; Burchell et al., 1983).
Sera
Sera were obtained from 96 healthy blood donors
(48 males, 48 females), 52 patients with non-
malignant diseases of breast (28 fibroadenoma, 15
fibrocystic, 2 mastalgia, 2 abscess, 4 other), 91
patients with breast cancer (14 with stage I and II
prior to surgery, 45 in apparent remission 10 days-
25 years after surgery and 32 with metastatic breast
carcinoma prior to any treatment).
Sera were also obtained from patients with neo-
plastic and non-neoplastic diseases of liver and
gastrointestinal tract (32 non-malignant diseases of
liver, 18 non-malignant disease of pancreas, 17 non-
malignant disease of colon, 42 carcinoma of colon,
8 primary hepatocellular carcinoma, 33 metastases
to the liver, 8 cholangiocarcinoma, 8 bile duct
stricture). Serum samples were stored at -200C
until required for analysis. Sera were frozen and
thawed once only prior to assaying.
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ELISA method
One of the reasons for the failure of existing
conventional 'sandwich' ELISA systems to detect
small amounts of circulating antigen might be that
the antigen is complexed specifically or non-specifi-
cally with other serum components and therefore
escapes detection by antibody. One way to expose
the antigen is to disrupt complexes using acidic
conditions, for example citric acid at pH 2.0 (Feller
et al., 1985). HMFGI and HMFG2 were directly
conjugated to phosphatase making the method a
simple one step procedure to minimise the
proportion of false positive results (Ishikawa et al.,
1983) (IQ [Bio] Ltd, Cambridge).
Twenty p1 of serum were added to 250 u1 of
citrate buffer pH 2.0, and 501p of this mixture was
added to wells of previously glutaraldehyde treated
microtitre plates. This was dried overnight at 37C
in a sterile fume cupboard to comply with Health
and Safety requirements. The plates were then blocked
with 0.02% gelatin and washed with 0.05% Tween
20 in PBS containing 0.2% casein. To each well,
100kil of a 400ngml-1 monoclonal antibody
conjugate with phosphatase and diluted in PBS
with Tween, was added and incubated at 4°C
overnight. Following further washes, 100pI of
substrate buffer (one tablet of Sigma 104
phosphatase to 5ml of diethanolanine (BDH) 5%
w/v +0.02mm Mg L/2) was added and incubated
at 30°C in the dark for 30min. Plates were read at
405nm.
Representative samples (positive and negative
controls) of the same sera were dried down using
PBS (pH 7.0) alone and were compared to the sera
dried down with the low pH method. It was found
that the positive controls were lost when using PBS
alone. Therefore the low pH has a significant effect
but we do not know whether the same effect can be
achieved using a different method of fixation and
disruption of serum (work in progress).
Results
HMFGJ and HMFG2 assay
Several parameters have been examined and our
findings (data not shown in this manuscript) were
that for HMFG1 and HMFG2 and using human
milk fat globule membrane (HMFG), and partially
deglycosylated HMFG (Taylor-Papadimitriou,
personal communication) as antigen we could
detect down to 2-4ng HMFG. We used this value
as the operational cut-off level, established by
examining normal blood donors, the cut-off point
being the mean of all samples plus 2 s.d. Although
results are expressed as optical density units they
can also be converted to ng1-1 HMFG antigen.
For each assay a standard curve was performed.
We found (data not shown) that the interassay and
intra-assay variations were always <10% and
usually between 3 and 5%.
The levels of circulating antigens detected by
antibodies HMFG1 and HMFG2 are shown in
Figures 1 and 2. The levels of antigens are
expressed directly as optical density OD (vertical
axis) units.
Data are shown for healthy controls, patients
with non-malignant disease of breast, patients with
stage I and II carcinoma of the breast prior to
surgery, patients in clinical remission from breast
cancer after surgery, and patients with advanced
metastatic breast cancer prior to treatment.
As can be seen the HMFG1 antigen was elevated
(above an operationally defined normal level of
0.133 OD) in 6% of healthy controls, in 17% of
patients with non-neoplastic diseases of breast, in
50% of patients with stage I or II breast cancer
prior to surgery, in 17% of patients in apparent
remission from breast cancer and in 69% of
patients with metastatic breast cancer prior to treat-
ment. HMFG2 antigen was elevated (above an
operationally defined normal level of 0.133 OD) in
3% healthy controls, 4% of women with non-
malignant diseases of breast, 50% of women with
stage I or II breast cancer before surgery, 47% of
patients in apparent remission from breast cancer
and 72.8% of patients with metastatic breast
cancer. Three patients with stage IV disease who had
responded well to treatment had undetectable
levels of both HMFG1 and HMFG2 antigen. It is
important to state, however, that the numbers of
patients with benign breast disease are too small
to be able to draw firm conclusions on the
incidence of raised HMFG as detected by HMFG1
and HMFG2 in this assay; in a more recent study
(results not shown) of 31 patients with benign
breast dise'ase we found elevated HMFG levels as
detected by HMFG2 in 13 (41%).
Sera were tested in 11 patients with stage I and II
disease before and after surgery. In patients with
completely resected tumours HMFG1 and HMFG2
levels that were elevated before surgery became
undetectable by the 30th postoperative day.
The proportion of positive sera in patients with
other types of benign or malignant disease is shown
in Table I. These markers do not appear to
discriminate between malignant and non-malignant
diseases of the liver and gastrointestinal tract.
Discussion
In this study we describe a new and simple ELISA
method with a low pH step to dissociate and fixLOW pH ELISA METHOD IN BREAST CANCER
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Figure 1 HMFGI serum levels in healthy controls and in patients with benign and malignant breast disease.
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Figure 2 HMFG2 serum levels in healthy controls and in patients with benign and malignant breast disease.
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Table I HMFG1 and HMFG2 serum levels in patients with neoplastic and non-
neoplastic diseases of liver, pancreas and colon
HMFGI HMFG2
Tissue type No. Positivea % Positivea %
Non-malignant diseases of liver 32 9 28 11 34
Non-malignant diseases of pancreas 17 1 5.8 2 12
Non-malignant diseases of colon 17 2 12 3 18
Bile duct structure 8 7 88 2 25
Primary hepatocellular carcinoma 8 4 50 3 37
Hepatic metastases 33 13 39 9 27
Carcinoma colon 42 11 26 11 26
Cholangiocarcinoma 8 7 88 3 37
Non-malignant diseases TOTAL 74 19 31 18 27
Malignant diseases TOTAL 91 35 38 26 28
aIndicates serum level above operational normal cut-off level of 0.133 OD.
serum incorporating two monoclonal antibodies
HMFG1 and HMFG2 for the detection of circu-
lating tumour associated antigens in patients with
breast cancer. Other methods incorporating conven-
tional sandwich techniques (Burchell & Taylor-
Papadimitriou, 1984) and using the same antibodies
HMFG1 and HMFG2 have shown elevation of
antigen in only 30-50% of patients with metastatic
breast cancer and 5-16% of control sera. Therefore
the new method described here appears to be more
sensitive than the previous one. Ceriani et al. (1982)
showed that a 46Kdmol. wt human mammary
epithelial antigen detected by monoclonal anti-
bodies is elevated in the sera of patients with
disseminated cancer. That 46Kd molecule is
probably distinct from the antigens detected by
HMFG1 and HMFG2. Other breast epithelial
antigens defined by monoclonal antibodies such as
antibody MF3 (Hayes et al., 1985), antibody
F36/22 (Papsidero et al., 1984) and antibody 24-
17.2 (Thomson et al., 1983) have been detected in
increased amounts in the sera of patients with
metastatic breast cancer. These assays developed
using conventional sandwich techniques appear to
be of promise in the monitoring of patients with
metastatic disease. No direct comparison has been
made between these assays and the new low pH
method. A low pH method failed to discriminate
satisfactorily between benign and malignant breast
disease and has poor reproducibility (Feller et al.,
1985). The reasons for the apparent discrepancy
with the previous method may be in the use of (a)
different monoclonal antibodies, (b) different
methodology, i.e. the new system involves a one-
step procedure whilst the previous assay used a
two-step procedure.
It is of interest to note that - 50% of patients
with stage I and II disease had elevated serum
HMFG1 and HMFG2 markers prior to surgery
and that 46.6% of patients in apparent clinical
remission had elevated HMFG2 antigen. It remains
to be determined whether this finding is of any
prognostic value (Wilkinson et al., 1984), e.g. in
defining a subgroup of patients with microscopic
metastases that may benefit from adjuvant therapy.
HMFG2 performed better than HMFG1 in that it
detected a higher percentage of patients with breast
cancer.
A reliable serum assay for monitoring the
response to therapy in patients with breast cancer
would be an important adjunct to clinical
management. Patients with metastatic breast cancer
often receive chemotherapy, hormonal or other
forms of therapy. It would be useful to have a non-
invasive, rapid and correct determination of
response to treatment that may prevent unnecessary
morbidity from ineffective therapy. The detection of
elevated HMFG as assayed by HMFG1 and
HMFG2 low pH method would not be helpful in
distinguising patients with breast cancer from those
with other pathologies such as ovarian carcinoma,
cholangiocarcinoma or bile duct stricture, etc.
(Table I), but could be of clinical value in
monitoring the response to treatment in the
majority of patients with metastatic breast cancer.
We are grateful to the following for their help: W.F.
Bodmer, C.G. McKenzie, D. Moss, J. Taylor-
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